|
|
 |
|
Viewing report
|
|
|
|
Drug Reconstitution at the Point-of-Care: Therapeutic Markets, Technologies, Strategies, and Prospects
Greystone Associates, Jan 2012
The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed – a distribution strategy referred to as the ‘Cold Chain'. Alternatively, proteins can be formulated as powders (lyophilization).
Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.
HIGHLIGHTS
- Analyzes therapeutic demand drivers and evaluates the market impact and potential of commercial drug reconstitution systems
- Provides analysis of injectable lyophilized drugs and assess key market segments, market dynamics and market demographics
- Forecasts Injectable drug product demand by indication and therapy to 2016
- Profiles reconstitution system suppliers, their product activities, business strategies, and corporate alliances and affiliations
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
